Climb Bio outlines budoprutug development strategy; Phase 1b pMN data shows 60% remission

Climb Bio, Inc.

Approximately $218M cash at Sept 30, 2024; expected to fund operations through 2027.
Phase 1b pMN: 3/5 patients achieved complete remission; rapid B-cell depletion and anti-PLA2R reductions.
Plans to initiate Phase 1b SLE trial and Phase 2 ITP trial in first half 2025, subject to regulatory clearance.
Subcutaneous formulation advancing; non-clinical data expected first half 2025.
Full pMN Phase 1b data to be presented at ASN Kidney Week on Oct 24, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.